Four-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study

  • Jordan M. Estroff
  • , Joseph Devlin
  • , Lara Hoteit
  • , Adnan Hassoune
  • , Matthew D. Neal
  • , Joshua B. Brown
  • , Liling Lu
  • , Shannon Kotch
  • , Joshua P. Hazelton
  • , Ashton B. Christian
  • , Eric O. Yeates
  • , Jeffry Nahmias
  • , Lewis E. Jacobson
  • , Jamie Williams
  • , Kevin M. Schuster
  • , Rick O'Connor
  • , Gregory R. Semon
  • , Angela D. Straughn
  • , Daniel Cullinane
  • , Tanya Egodage
  • Michelle Kincaid, Allison Rollins, Richard Amdur, Babak Sarani

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)541-545
Number of pages5
JournalJournal of Trauma and Acute Care Surgery
Volume97
Issue number4
DOIs
StatePublished - Oct 1 2024
Externally publishedYes

ASJC Scopus Subject Areas

  • Surgery
  • Critical Care and Intensive Care Medicine

Keywords

  • DOAC
  • PCC
  • prothrombin complex concentrate
  • reversal

Cite this